Patents by Inventor Richard L. Monaghan

Richard L. Monaghan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7294646
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of a mammalian species, particularly humans.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: November 13, 2007
    Assignee: Merck & Co. Inc.
    Inventors: Maria L. Garcia, Michael A. Goetz, Gregory J. Kaczorowski, Owen B. McManus, Richard L. Monaghan, William R. Strohl, Jan S. Tkacz
  • Patent number: 5578581
    Abstract: An active avermectin analogue which can be produced by directed biosynthesis is described. The compound, named 26-R-Avermectin B.sub.
    Type: Grant
    Filed: April 26, 1994
    Date of Patent: November 26, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Prakash S. Masurekar, Wesley L. Shoop, Michael A. Wallace, Richard L. Monaghan
  • Patent number: 5441987
    Abstract: A compound having the formula ##STR1## which is useful as an antifungal agent and for the treatment and control of several agricultural phytopathogens, including Phytophthora infestans, is disclosed.
    Type: Grant
    Filed: August 12, 1994
    Date of Patent: August 15, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Guy H. Harris, James E. Curotto, Robert A. Giacobbe, Suzanne M. Mandala, Richard L. Monaghan, Richard K. Jansson, Joan A. Lasota
  • Patent number: 5324720
    Abstract: Inhibition of renal cancer, melanoma, colon cancer, lung cancer and leukemia cells by administration of compounds from the bafilomycin and hygrolidin groups of compounds.
    Type: Grant
    Filed: March 20, 1992
    Date of Patent: June 28, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Tom G. Holt, Richard L. Monaghan
  • Patent number: 5317031
    Abstract: Cholesterol lowering compounds and compositions are formed from the photochemical treatment of the Zaragozic Acids followed by esterification. These compounds and compositions are active squalene synthetase inhibitors useful in the treatment of hypercholesterolemia.
    Type: Grant
    Filed: November 24, 1992
    Date of Patent: May 31, 1994
    Assignee: Merck & Co., Inc.
    Inventors: John G. MacConnell, Byron H. Arison, George A. Doss, Richard L. Monaghan
  • Patent number: 5306716
    Abstract: Inhibition of renal cancer, melanoma, colon cancer, lung cancer and leukemia cells by administration of compounds from the bafilomycin and hygrolidin groups of compounds.
    Type: Grant
    Filed: March 20, 1992
    Date of Patent: April 26, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Tom G. Holt, Richard L. Monaghan
  • Patent number: 5278320
    Abstract: Compounds of Structural Formula (I) ##STR1## are produced by chemical modification of directed biosynthesis products. These compounds are squalene synthetase inhibitors and thus useful as cholesterol lowering agents, antifungal agents and cancer treatment agents.
    Type: Grant
    Filed: September 11, 1992
    Date of Patent: January 11, 1994
    Assignee: Merck & Co., Inc.
    Inventor: Richard L. Monaghan
  • Patent number: 5196327
    Abstract: A mixture of derivatives of 2-amino-3,4,5,14-tetrahydroxy-6-eicosenoic acid has been isolated from a culture medium after cultivation of microorganisms belonging to the genus Aspergillus. The compounds are useful as antifungal agents.
    Type: Grant
    Filed: May 8, 1991
    Date of Patent: March 23, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Maria B. Lopez, Richard L. Monaghan
  • Patent number: 5019593
    Abstract: A mixture of derivatives of 2-amino-3,4,5,14-tetrahydroxy-6-eicosenoic acid has been isolated from a culture medium after cultivation of microorganisms belonging to the genus Aspergillus. The compounds are useful as antifungal agents.
    Type: Grant
    Filed: July 29, 1987
    Date of Patent: May 28, 1991
    Assignee: Merck & Co., Inc.
    Inventors: George M. Garrity, Maria B. Lopez, Otto D. Hensens, Richard L. Monaghan, Deborah L. Zink
  • Patent number: 5008187
    Abstract: A new antifungal agent which exhibits a moderately broad spectrum of activity towards filamentous fungi and also against Cryptococcus species of the yeast fungi, and which has been isolated from a solid stationary fermentation of an unidentified species of Fusarium is described.
    Type: Grant
    Filed: December 1, 1988
    Date of Patent: April 16, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Louis Chaiet, Sheldon B. Zimmerman, Richard L. Monaghan, George M. Garrity
  • Patent number: 4968608
    Abstract: An antifungal agent produced by cultivation of Zalerion arboricola is a cyclic lipopeptide with very high activity against human pathogens and of very low mammalian toxicity. Its production and isolation are also described.
    Type: Grant
    Filed: October 7, 1987
    Date of Patent: November 6, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Robert A. Giacobbe, Sagrario M. Del Val, Richard L. Monaghan, Robert E. Schwartz
  • Patent number: 4847284
    Abstract: A novel pyrrolidinol isolated from the fermentation of Aspergillus ochraceus and certain derivatives thereof are described. The compounds are broad spectrum antifungal agents.
    Type: Grant
    Filed: March 23, 1988
    Date of Patent: July 11, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Robert E. Schwartz, Janet C. Onishi, Richard L. Monaghan, Jerrold M. Liesch, Otto D. Hensens
  • Patent number: 4828992
    Abstract: The process for the manufacture of the compound of the general structural formula ##STR1## which is a 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) synthase inhibitor and useful as an antihypercholesterolemic agent for the treatment of disease in which the inhibition of cholesterol biosynthesis would be useful, and which is an antifungal agent is disclosed.
    Type: Grant
    Filed: February 3, 1986
    Date of Patent: May 9, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Sagrario M. Del Val, Maria I. M. Fernandez, Richard L. Monaghan
  • Patent number: 4695544
    Abstract: A process for preparing the compound having Formula I and several minor related compounds. ##STR1## The compound of Formula I and the several minor related compounds are antagonists of cholecystokinin (CCK). CCK antagonists are useful in the treatment and prevention of disorders of the gastrointestinal, central nervous and appetite regulatory systems of animals, especially humans.
    Type: Grant
    Filed: March 15, 1985
    Date of Patent: September 22, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Monaghan, Michael A. Goetz, Raymond S. Chang
  • Patent number: 4681846
    Abstract: Process for the preparation of difficidin and derivative antibacterial compounds of the formula: ##STR1## where R.sub.a and R.sub.b are members independently selected from the group consisting of hydrogen; alkali metal and alkaline earth metal cations; ammonium; and substituted ammonium; and R.sup.1 is hydrogen or hydroxy.
    Type: Grant
    Filed: May 6, 1985
    Date of Patent: July 21, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth E. Wilson, Richard L. Monaghan, Cheryl DeRiso, Sheldon B. Zimmerman, Otto D. Hensens, James E. Flor, Sagrario M. Del Val, Maria I. M. Fernandez
  • Patent number: 4670466
    Abstract: R-(Z)-4-amino-3-chloro-2-pentenedioic acid is a novel antibacterial and isolated from Streptomyces viridogenes MA5450, ATCC 39387.
    Type: Grant
    Filed: September 20, 1985
    Date of Patent: June 2, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Louis Chaiet, Sheldon B. Zimmerman, Richard L. Monaghan, Maria I. Martin
  • Patent number: 4600691
    Abstract: R-(Z)-4-amino-3-chloro-2-pentenedioic acid is a novel antibacterial and isolated from Streptomyces viridogenes MA5450, ATCC 39387.
    Type: Grant
    Filed: April 3, 1985
    Date of Patent: July 15, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Louis Chaiet, Richard L. Monaghan, Sheldon B. Zimmerman, Maria I. M. Fernandez
  • Patent number: 4545991
    Abstract: Difficidin and derivative antibacterial compounds of the formula: ##STR1## where R.sub.a and R.sub.b are members independently selected from the group consisting of hydrogen; alkali metal and alkaline earth metal cations; ammonium; and substituted ammonium; and R.sup.1 is hydrogen or hydroxy.
    Type: Grant
    Filed: June 13, 1983
    Date of Patent: October 8, 1985
    Assignee: Merck & Co., Inc.
    Inventors: Sheldon B. Zimmerman, Kenneth E. Wilson, Richard L. Monaghan, Sagrario M. Del Val, Maria I. M. Fernandez, Otto D. Hensens, James E. Flor, Cheryl Deriso
  • Patent number: 4540575
    Abstract: New fermentation products useful in the treatment of tardive dyskinesia by inhibition of choline oxidase are produced by fermentation of a nutrient medium with a microorganism, Streptomyces hygroscopicus.
    Type: Grant
    Filed: May 6, 1983
    Date of Patent: September 10, 1985
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Monaghan, Yu-Lin Kong
  • Patent number: 4530790
    Abstract: The compound having Formula I and several minor related compounds are produced by the aerobic fermentation of Aspergillus alliaceus Thom and Church, ATCC No. 20655 or ATCC No. 20656. ##STR1## The compound of Formula I and the several minor related compounds are antagonists of cholecystokinin (CCK). CCK antagonists are useful in the treatment and prevention of disorders of the gastrointestinal, central nervous and appetite regulatory systems of animals, especially humans.
    Type: Grant
    Filed: July 1, 1983
    Date of Patent: July 23, 1985
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Monaghan, Michael A. Goetz, Raymond S. L. Chang